Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | PYGL | P06737 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.51 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ESRRA | P11474 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8919414 | 0.89 | HTT (0.54) | ALDH1A1PYGLKMT2ARORCSMN1; SMN2 | |
| SCHEMBL11636304 | 0.85 | ALDH1A1 (0.58) | ALDH1A1PYGLKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7936658 | 0.85 | KMT2A (0.54) | ALDH1A1PYGLKMT2AMEN1RORC | |
| SCHEMBL3786387 | 0.85 | CA1 (0.58) | ALDH1A1KMT2AMEN1RORCSMN1; SMN2 | |
| SCHEMBL14341158 | 0.84 | PYGL (0.50) | ALDH1A1PYGLKMT2AMEN1RORC | |
| SCHEMBL9472463 | 0.84 | PYGL (0.50) | ALDH1A1PYGLKMT2AMEN1RORC | |
| SCHEMBL22092486 | 0.84 | SLC6A3 (0.63) | ALDH1A1PYGLKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4548035 | 0.84 | EPHX1 (0.70) | KMT2AMEN1RORCSMN1; SMN2MAPT | |
| SCHEMBL3249655 | 0.83 | ALDH1A1 (0.73) | ALDH1A1PYGLKMT2AMEN1MAPT | |
| SCHEMBL2388970 | 0.82 | EPHX1 (0.70) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| EP-0473552-A1 | Process for the preparation of halogenated aromatic primary amines | CIBA-GEIGY AG (CH) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ALDH1A1 4339/4885PYGL 3727/4885KMT2A 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.